Accolade (NASDAQ: ACCD)
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | (EXPECTED) 2022-06-30 | |||||
REV | 81.970M |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.510 | -0.1500 | ||||
REV | 91.570M | 93.756M | 2.186M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Accolade (NASDAQ: ACCD) through any online brokerage.
Other companies in Accolade’s space includes: Sema4 Holdings (NASDAQ:SMFR), Aveanna Healthcare Hldgs (NASDAQ:AVAH), Cross Country Healthcare (NASDAQ:CCRN), ATI Physical Therapy (NYSE:ATIP) and Hims & Hers Health (NYSE:HIMS).
The latest price target for Accolade (NASDAQ: ACCD) was reported by Goldman Sachs on Thursday, May 26, 2022. The analyst firm set a price target for 15.00 expecting ACCD to rise to within 12 months (a possible 82.04% upside). 26 analyst firms have reported ratings in the last year.
The stock price for Accolade (NASDAQ: ACCD) is $8.24 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Accolade.
Accolade’s Q1 earnings are confirmed for Thursday, June 30, 2022.
There is no upcoming split for Accolade.
Accolade is in the Health Care sector and Health Care Providers & Services industry. They are listed on the NASDAQ.